TY - JOUR
T1 - Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics
AU - Shigeyasu, Kunitoshi
AU - Tazawa, Hiroshi
AU - Hashimoto, Yuuri
AU - Mori, Yoshiko
AU - Nishizaki, Masahiko
AU - Kishimoto, Hiroyuki
AU - Nagasaka, Takeshi
AU - Kuroda, Shinji
AU - Urata, Yasuo
AU - Goel, Ajay
AU - Kagawa, Shunsuke
AU - Fujiwara, Toshiyoshi
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background Molecular-based companion diagnostic tests are being used with increasing frequency to predict their clinical response to various drugs, particularly for molecularly targeted drugs. However, invasive procedures are typically required to obtain tissues for this analysis. Circulating tumour cells (CTCs) are novel biomarkers that can be used for the prediction of disease progression and are also important surrogate sources of cancer cells. Because current CTC detection strategies mainly depend on epithelial cell-surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs. Methods We developed a new approach to capture live CTCs among millions of peripheral blood leukocytes using a green fluorescent protein (GFP)-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan). Results Our biological capturing system can image epithelial and mesenchymal tumour cells with telomerase activities as GFP-positive cells. After sorting, direct sequencing or mutation-specific PCR can precisely detect different mutations in KRAS, BRAF and KIT genes in epithelial, mesenchymal or epithelial-mesenchymal transition-induced CTCs, and in clinical blood samples from patients with colorectal cancer. Conclusions This fluorescence virus-guided viable CTC capturing method provides a non-invasive alternative to tissue biopsy or surgical resection of primary tumours for companion diagnostics.
AB - Background Molecular-based companion diagnostic tests are being used with increasing frequency to predict their clinical response to various drugs, particularly for molecularly targeted drugs. However, invasive procedures are typically required to obtain tissues for this analysis. Circulating tumour cells (CTCs) are novel biomarkers that can be used for the prediction of disease progression and are also important surrogate sources of cancer cells. Because current CTC detection strategies mainly depend on epithelial cell-surface markers, the presence of heterogeneous populations of CTCs with epithelial and/or mesenchymal characteristics may pose obstacles to the detection of CTCs. Methods We developed a new approach to capture live CTCs among millions of peripheral blood leukocytes using a green fluorescent protein (GFP)-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan). Results Our biological capturing system can image epithelial and mesenchymal tumour cells with telomerase activities as GFP-positive cells. After sorting, direct sequencing or mutation-specific PCR can precisely detect different mutations in KRAS, BRAF and KIT genes in epithelial, mesenchymal or epithelial-mesenchymal transition-induced CTCs, and in clinical blood samples from patients with colorectal cancer. Conclusions This fluorescence virus-guided viable CTC capturing method provides a non-invasive alternative to tissue biopsy or surgical resection of primary tumours for companion diagnostics.
UR - http://www.scopus.com/inward/record.url?scp=84924405704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924405704&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2014-306957
DO - 10.1136/gutjnl-2014-306957
M3 - Article
C2 - 24870621
AN - SCOPUS:84924405704
SN - 0017-5749
VL - 64
SP - 627
EP - 635
JO - Gut
JF - Gut
IS - 4
ER -